As an authority in radiation oncology,
Dr. Khuntia joining the board of directors validates BNCT and
the work TAE Life Sciences is doing to make it a mainstay of modern
cancer care
IRVINE,
Calif., April 17, 2024 /PRNewswire/ -- TAE Life
Sciences, a pioneer in advancing Boron Neutron Capture Therapy
(BNCT) for cancer treatment, proudly announces the appointment of
Dr. Deepak "Dee" Khuntia, M.D., FASTRO, to its esteemed Board of
Directors. Dr. Khuntia brings unparalleled expertise and invaluable
insights to the board, further strengthening TAE Life Sciences'
position as a pioneer in the field of radiation oncology.
As Senior Vice President of Medical Affairs and Chief Medical
Officer at Varian, a Siemens Healthineers Company, Dr. Khuntia has
been instrumental in revolutionizing cancer treatment and advancing
cardiac radiosurgery technologies worldwide. With a distinguished
career spanning decades, Dr. Khuntia has established himself as one
of the foremost authorities in radiation oncology, particularly in
the treatment of brain tumors, head and neck cancer, and lung
cancer.
"Dr. Deepak Khuntia brings unparalleled expertise and
leadership in the field of radiation oncology, with an emphasis on
many of the same types of cancers we're targeting with BNCT," said
Rob Hill, CEO of TAE Life Sciences.
"I'm confident that he'll prove invaluable as we continue to
innovate and develop groundbreaking cancer treatment solutions. Dr.
Khuntia's presence on our board further validates our commitment to
revolutionizing radiation oncology and driving mainstream adoption
of BNCT as a treatment modality."
Dr. Khuntia expressed his excitement about joining TAE Life
Sciences' board, stating, "I believe in the promising future of
Boron Neutron Capture Therapy (BNCT) and its potential to transform
the landscape of radiation oncology. I look forward to working
closely with the board and management team to drive advancements in
cancer care and improve patient outcomes."
With Dr. Khuntia's appointment, TAE Life Sciences continues to
attract top talent and solidify its position as a leader in the
development of innovative cancer treatment solutions. The company
remains committed to its mission of providing hope and healing to
patients worldwide through BNCT's precise cancer-targeting
capabilities.
For more information about TAE Life Sciences, Alphabeam, and the
company's proprietary boronated BNCT drugs, please visit
www.taelifesciences.com.
About TAE Life Sciences
TAE Life Sciences is a
privately held biotechnology company committed to developing a new
biologically targeted radiation therapy based on Boron Neutron
Capture Therapy (BNCT). TAE Life Sciences is the only company
developing the next-generation targeted boron drugs and low-energy
accelerator-based neutron system optimized for an in-hospital BNCT
program that delivers cancer-killing radiation with cellular-level
precision to treat patients with aggressive and refractory cancers.
TAE Life Sciences' Alphabeam™ BNCT system and proprietary
boronated drugs are still in the investigational stage, and not
available commercially. More information about TAE Life
Sciences is available at www.taelifesciences.com.
Press Contact:
Michael Farino
New Era Communications
949-346-1984
TAE@newerapr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tae-life-sciences-welcomes-dr-deepak-dee-khuntia-to-its-board-of-directors-302119264.html
SOURCE TAE Life Sciences